Marco Donia: Therapeutic Cancer Vaccines – update in Melanoma
Marco Donia, at the
“Therapeutic Cancer Vaccines: update in Melanoma, March 2024 (slides available, link at the bottom of the post). I was recently invited to the Finnish Melanoma Group 2024 Spring Meeting to provide an update on a field again on the rise: Melanoma Cancer Vaccines.
A quick summary of key topics and key references is provided below:
- Components of a cancer vaccine: Tumor antigens, formulations, immune adjuvants, delivery vehicles.
- Antigens targeted: cancer cell antigens or or antigens of the tumor microenvironment.
Recent results in Metastatic Melanoma:
- IDO/PD-L1 vaccine and phase 3 completed enrolment.
- FixVac, phase 2 ongoing.
- NEO-PV-01.
- EVX-01, phase 2 ongoing.
- Recent Results in high-risk Resected Melanoma: mRNA-4157, phase 3 ongoing.
Want to download and use my slides? You can do via this link (email required).
If you know other vaccines for melanoma in development, please comment and I will update the post! Thanks to the Finnish Melanoma Group and its (now, past) chair, Micaela Hernberg from HUS Helsinki University Hospital, for the invite and the great scientific exchange.”
Source: Marco Donia/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023